Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Wharton

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Postgraduate Medicine|November 15, 2021
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practiceSean Wharton, Melanie Davies, Dror Dicker, et al.
Diabetes, Obesity & Metabolism|September 12, 2025
A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on CanadaJames Kim, Paolo Raggi, Anne-Marie Carreau, et al.
Obesity (Silver Spring, Md.)|August 24, 2019
Effectiveness of a Community-Based Weight Management Program for Patients Taking Antidepressants and/or AntipsychoticsSean Wharton, Jennifer L Kuk, Lana Petrova, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|August 16, 2021
Sequential diets and weight loss: Including a low-carbohydrate high-fat diet with and without time-restricted feedingRebecca A G Christensen, Sasha High, Sean Wharton, et al.
Journal of General Internal Medicine|July 27, 2025
Advancing Person-Centered Care in the New Era of Obesity TreatmentLeah M Schumacher, Sarah Le Brocq, Sean Wharton, et al.
The Lancet. Diabetes & Endocrinology|September 17, 2025
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trialSean Wharton, Paula Freitas, Jøran Hjelmesæth, et al.
International Journal of Obesity (2005)|June 4, 2021
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trialSean Wharton, Peter Yin, Melonie Burrows, et al.
BMC Primary Care|May 3, 2022
The i-ACT™ in Obesity educational intervention: a pilot study on improving Canadian family physician care in obesity medicineSean Wharton, David Macklin, Marie-Philippe Morin, et al.
The Canadian Journal of Cardiology|May 11, 2006
Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialistsJeff S Healey, Sean Wharton, Saif Al-Kaabi, et al.
Cardiovascular Diabetology|June 6, 2025
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetesSean Wharton, Julio Rosenstock, Manige Konige, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Postgraduate Medicine|November 15, 2021
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practiceSean Wharton, Melanie Davies, Dror Dicker, et al.
Diabetes, Obesity & Metabolism|September 12, 2025
A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on CanadaJames Kim, Paolo Raggi, Anne-Marie Carreau, et al.
Obesity (Silver Spring, Md.)|August 24, 2019
Effectiveness of a Community-Based Weight Management Program for Patients Taking Antidepressants and/or AntipsychoticsSean Wharton, Jennifer L Kuk, Lana Petrova, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|August 16, 2021
Sequential diets and weight loss: Including a low-carbohydrate high-fat diet with and without time-restricted feedingRebecca A G Christensen, Sasha High, Sean Wharton, et al.
Journal of General Internal Medicine|July 27, 2025
Advancing Person-Centered Care in the New Era of Obesity TreatmentLeah M Schumacher, Sarah Le Brocq, Sean Wharton, et al.
The Lancet. Diabetes & Endocrinology|September 17, 2025
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trialSean Wharton, Paula Freitas, Jøran Hjelmesæth, et al.
International Journal of Obesity (2005)|June 4, 2021
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trialSean Wharton, Peter Yin, Melonie Burrows, et al.
BMC Primary Care|May 3, 2022
The i-ACT™ in Obesity educational intervention: a pilot study on improving Canadian family physician care in obesity medicineSean Wharton, David Macklin, Marie-Philippe Morin, et al.
The Canadian Journal of Cardiology|May 11, 2006
Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialistsJeff S Healey, Sean Wharton, Saif Al-Kaabi, et al.
Cardiovascular Diabetology|June 6, 2025
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetesSean Wharton, Julio Rosenstock, Manige Konige, et al.
Pageof 10